中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
16期
93-94
,共2页
奥氮平%老年痴呆%疗效%不良反应
奧氮平%老年癡呆%療效%不良反應
오담평%노년치태%료효%불량반응
Olanzapine%Senile dementia%Efficacy%Adverse reaction
目的：研究奥氮平治疗老年痴呆精神行为障碍的临床疗效及安全性分析。方法将该院于2011年7月-2013年7月收治的80例老年痴呆伴精神行为障碍患者抽签随机分为观察组与对照组，两组均为40例，观察组采取奥氮平治疗，对照组给予利培酮治疗，比较两组治疗前后阿尔茨海默病行为病理评定量表(BEHAVE-AD)变化及不良反应发生情况。结果治疗后两组BEHAVE-AD评分均显著下降，与治疗前比较(P<0.05)，治疗前及治疗后15 d两组比较差异无统计学意义(P>0.05)，观察组治疗后30、60 d时BEHAVE-AD评分分别为(16.64±7.48)、(5.76±4.61)分与对照组(22.60±8.30)、(8.55±4.97)分比较差异有统计学意义(P<0.05)；观察组乏力、激惹、失眠、嗜睡、肝功能异常、椎体外系反应分别为7.50%、5.00%、2.50%、2.50%、2.50%、2.50%，总发生率22.50%，对照组分别为2.50%、5.00%、8.00%、7.50%、0.00%、20.00%、总发生率45.00%，组间比较观察组差异有统计学意义(P<0.05)。结论奥氮平治疗老年痴呆精神行为障碍效果显著，且安全性较高，临床价值优于利培酮，建议作为老年痴呆精神行为障碍的首选药物治疗方式进行推广。
目的：研究奧氮平治療老年癡呆精神行為障礙的臨床療效及安全性分析。方法將該院于2011年7月-2013年7月收治的80例老年癡呆伴精神行為障礙患者抽籤隨機分為觀察組與對照組，兩組均為40例，觀察組採取奧氮平治療，對照組給予利培酮治療，比較兩組治療前後阿爾茨海默病行為病理評定量錶(BEHAVE-AD)變化及不良反應髮生情況。結果治療後兩組BEHAVE-AD評分均顯著下降，與治療前比較(P<0.05)，治療前及治療後15 d兩組比較差異無統計學意義(P>0.05)，觀察組治療後30、60 d時BEHAVE-AD評分分彆為(16.64±7.48)、(5.76±4.61)分與對照組(22.60±8.30)、(8.55±4.97)分比較差異有統計學意義(P<0.05)；觀察組乏力、激惹、失眠、嗜睡、肝功能異常、椎體外繫反應分彆為7.50%、5.00%、2.50%、2.50%、2.50%、2.50%，總髮生率22.50%，對照組分彆為2.50%、5.00%、8.00%、7.50%、0.00%、20.00%、總髮生率45.00%，組間比較觀察組差異有統計學意義(P<0.05)。結論奧氮平治療老年癡呆精神行為障礙效果顯著，且安全性較高，臨床價值優于利培酮，建議作為老年癡呆精神行為障礙的首選藥物治療方式進行推廣。
목적：연구오담평치료노년치태정신행위장애적림상료효급안전성분석。방법장해원우2011년7월-2013년7월수치적80례노년치태반정신행위장애환자추첨수궤분위관찰조여대조조，량조균위40례，관찰조채취오담평치료，대조조급여리배동치료，비교량조치료전후아이자해묵병행위병리평정량표(BEHAVE-AD)변화급불량반응발생정황。결과치료후량조BEHAVE-AD평분균현저하강，여치료전비교(P<0.05)，치료전급치료후15 d량조비교차이무통계학의의(P>0.05)，관찰조치료후30、60 d시BEHAVE-AD평분분별위(16.64±7.48)、(5.76±4.61)분여대조조(22.60±8.30)、(8.55±4.97)분비교차이유통계학의의(P<0.05)；관찰조핍력、격야、실면、기수、간공능이상、추체외계반응분별위7.50%、5.00%、2.50%、2.50%、2.50%、2.50%，총발생솔22.50%，대조조분별위2.50%、5.00%、8.00%、7.50%、0.00%、20.00%、총발생솔45.00%，조간비교관찰조차이유통계학의의(P<0.05)。결론오담평치료노년치태정신행위장애효과현저，차안전성교고，림상개치우우리배동，건의작위노년치태정신행위장애적수선약물치료방식진행추엄。
Objective To analyze the therapeutic efficacy and safety of olanzapine in treatment of mental and behavioral disorder of senile dementia. Methods In our hospilal from 2011 July to 2013 July were teeated 80 cases of senile dementia with mental and behavior disorder patients were randomly divided into observation group and control group, each of 40 cases, the observation group was taken olanzapine treatment, the control group were given risperidone treatment, compared behavior in Blzheimer's Dis-ease Rating Scale (BEHAVE-AD) and adverse reaction incidence changes of two groups before and after treatment. Results After treatment, BEHAVE-AD score of two groups were significantly decreased compared with those before treatment (P<0.05), before and after 15d treatment between two groups had no statistical significance (P> 0.05), the observation group after treatment 30d, 60d of BEHAVE-AD score were (16.64±7.48), (5.76±4.61) points and the control group (22.60±8.30), (8.55±4.97) points, observa-tion group were significantly lower (P<0.05);the fatigue, irritability, insomnia, drowsiness, abnormal liver function, extrapyramidal reaction observation group were 7.50%, 5%, 2.50%, 2.50%, 2.50%, 2.50%, the total incidence rate of 22.50%. The control group were 2.50%, 5%, 8%, 7.50%, 0%, 20%, the total incidence rate was 45%, comparison between groups found that observation group was significantly lower (P< 0.05). Conclusion Olanzapine treatment effect of senile dementia disorders spirit behavior is significant, and higher security, clinical value is superior to risperidone, suggested as a drug of first choice for senile dementia dis-orders behavior spirit promotion.
